TOKE Talk: Another Cannabis ETF Is Here
The 420 holiday, the annual ode to cannabis indulgences, is celebrated in April, but for marijuana and exchange traded funds investors, July 2019 has brought plenty to celebrate, too.
The Cambria Cannabis ETF (CBOE: TOKE) debuted Thursday, marking the second cannabis ETF launch this week and third this month.
With the debut of TOKE, there are now five cannabis ETFs listed in New York. At the start of 2019, there was just one. TOKE is a departure from the norm for Los Angeles-based Cambria. The issuer has gained acclaim for its unique lineup featuring deep value, momentum and shareholder yield strategies.
Some of the firm's well-known ETFs include the Cambria Shareholder Yield ETF (CBOE: SYLD), Cambria Global Value ETF (CBOE: GVAL), Cambria Global Momentum ETF (CBOE: GMOM) and the Cambria Tail Risk ETF (CBOE: TAIL).
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 — click here to learn more!
Why It's Important
TOKE “will target investing in approximately 20 to 50 of the top companies with exposure to the broad cannabis industry based on Cambria’s determination as to their exposure to the industry,” according to Cambria. “The Fund generally expects to invest in companies across a broad market capitalization spectrum of micro-, small-, and mid-capitalization stocks.”
TOKE debuted with 30 holdings. The fund identifies “companies across a range of market capitalizations that derive a significant portion of revenue from the legal sale, cultivation, production, or provision of cannabis-related products, services, or research,” notes Cambria.
Clearly, competition in the ETF space is intensifying, but TOKE has one obvious way of its setting itself apart from its established rivals: a lower fee. The four U.S.-listed cannabis ETFs that beat toke to market have annual expense ratios ranging from 0.70% to 0.75%.
TOKE is significantly cheaper with an annual fee of just 0.42%, or $42 on a $10,000 investment. That's not just inexpensive compared to other cannabis ETFs, it's cheap relative to standard broad market actively managed equity funds.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.